MRK vs MRNA
By Alex · Tickerpine
Merck & Co., Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | MRNA |
|---|---|---|
| Price | $147.76 | $223.37 |
| Market cap | $364.26B | $90.38B |
| P/E ratio | 149.3 | — |
| ROE | 5.06% | -34.50% |
| Profit margin | 3.64% | -110.45% |
| Revenue growth | 4.70% | 29.20% |
| Dividend yield | 2.30% | 0.00% |
| Beta | 0.12 | 1.17 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs MRNA in plain English
- MRK is the bigger company — about 4.0× the market cap of MRNA.
- MRK earns a higher return on equity (5% vs -35%).
- MRNA is growing revenue faster (29% vs 5%).
- MRK pays a dividend (2.30%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.